Cellular Immunotherapy Market, By Therapy Type (CAR T-Cell Therapy (Chimeric Antigen Receptor T-cell), TCR-T Cell Therapy (T-Cell Receptor T-cell), NK Cell Therapy (Natural Killer cell therapy), Dendritic Cell Therapy, Tumor-Infiltrating Lymphocytes (TIL) Therapy, Macrophage-Based Cell Therapy, and Others (emerging/novel cell types)), By Source (Autologous (patient-derived cells) and Allogeneic (donor-derived cells)), By Indication (Cancer (Hematologic Malignancies (e.g., leukemia, lymphoma, myeloma), Solid Tumors (e.g., lung, breast, melanoma, ovarian, glioblastoma)), Infectious Diseases (Viral Infections (e.g., HIV, HBV, HCV, COVID-19), Bacterial Infections (e.g., tuberculosis)), Autoimmune Disorders (Multiple Sclerosis, Rheumatoid Arthritis, Type 1 Diabetes), and Others), By Manufacturing Modality (Ex Vivo Cell Expansion and In Vivo Engineering), By End User (Hospitals and Clinics, Specialty Endocrinology and Obesity Centers, Ambulatory Surgical Centers (ASCs), Home Healthcare Services, and Others (Academic and Research Institutes, etc.)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)